Seeking Alpha EN

MYR GAAP EPS of $2.33 beats by $0.55, revenue of $973.54M beats by $75.81M

Feb 25, 2026 &02572525202628; 21:57 UTC seekingalpha.com Trending 3/5

Read original on seekingalpha.com ↗

↗

Positive for markets

Sentiment score: +80/100

High impact Medium-term (weeks)

WHAT THIS MEANS

Myriad Genetics ha superato le aspettative con un utile pro forma GAAP di $2,33 a share, un aumento di $0,55 rispetto alle previsioni, e un fatturato di $973,54 milioni, un aumento di $75,81 milioni rispetto alle previsioni.

AI CONFIDENCE

85% Very high

SENTIMENT GAUGE

NEWS POWER SCORE

AFFECTED ASSETS

↑

MYGN

MYGNStock

Expected to rise

Superamento delle aspettative per utile e fatturato

PRICE HISTORY

Loading chart...

⚡ SUGGESTED ACTION

Consigliamo di acquistare MYGN con un obiettivo di prezzo di $40,50, mantenendo una posizione di lungo termine.

KEY SIGNALS

Superamento delle aspettative per utile e fatturatoAumento della domanda per i prodotti della società

SECTORS INVOLVED

Biotecnologie

Analysis generated on Feb 26, 2026 at 03:15 UTC

Disclaimer: This analysis is generated by artificial intelligence for informational purposes only and does not constitute financial advice, investment recommendation, or solicitation. Original reporting by Seeking Alpha. Always conduct your own research and consult a qualified financial advisor before making investment decisions.

MYR GAAP EPS of $2.33 beats by $0.55, revenue of $973.54M beats by $75.81M

RELATED INTELLIGENCE